871361-88-5
基本信息
AKT抑制劑(SC66)
(2E,6E)-2,6-二(4-吡啶基亞甲基)環(huán)己酮
CS-2480
SC66
SC 66
(2E,6E)-2,6-Bis(4-pyridinylmethylene)-cyclohexanone
Cyclohexanone, 2,6-bis(4-pyridinylMethylene)-, (2E,6E)-
報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
2024/11/08 | HY-19832 | SC 66 SC66 | 871361-88-5 | 5mg | 550元 |
2024/11/08 | HY-19832 | SC 66 SC66 | 871361-88-5 | 10mM * 1mLin DMSO | 605元 |
2024/11/08 | HY-19832 | SC 66 SC66 | 871361-88-5 | 10mg | 770元 |
常見問題列表
Akt
|
SC66 inhibits cell viability and colony forming capacity of HCC cells with IC 50 s of 0.77,0.47,0.92,0.75 and 2.85 μg/mL at 72 hours for HepG2, Hep3B, PLC/PRF/5,HA22T/VGH and Huh7 cells. HepG2, HA22T/VGH and PLC/PRF/5 cells have similar IC 50 s of approximately 0.85 and 0.75 μg/mL at 48 and 72 hours, respectively. To determine whether the decrease in cell viability is related to apoptosis induction, TUNEL assays are performed in Hep3B and Huh7 cells treated with 1, 2 and 4 μg/mL of SC66 for 24 hours. In Hep3B cells the number of TUNEL-positive cells increased with increasing concentrations of SC66, whereas in Huh7 cells very few light brown-colored cells are observed only after treatment with 4 μg/mL SC66.
To demonstrate the effectiveness in vivo of SC66 on HCC, a mouse xenograft tumor model of Hep3B cells is used. When tumors became palpable, at a size of about 150 mm 3 , mice are randomized into three groups of 6 animals each. The treated group receive SC66 at 15 and 25 mg/kg twice a week via i.p. injection, while the untreated group receive the vehicle alone. Treatment with 25 mg/Kg SC66 significantly reduces tumor volume to 37% on day 17 when compared with tumors of the untreated group.